{"title":"Methotrexate-induced Neutropenia","authors":"KeshaAjaykumar Parmar, Maulin Mehta","doi":"10.4103/ajprhc.ajprhc_15_23","DOIUrl":null,"url":null,"abstract":"Various malignancies, autoimmune disorders such as rheumatoid arthritis (RA), and elective abortions commonly use methotrexate (MTX) for their treatment, which is a folate antagonist. Although many cases of the common side effects of MTX such as nausea, vomiting, and stomatitis have been reported, very few cases of MTX-induced neutropenia have been found in the literature. We have taken a case of neutropenia that developed after the patient took tablet MTX for RA. The case was studied and the causality assessment of the reported adverse drug reaction showed it to be in the category of “probable” according to the WHO-UMC causality categories.","PeriodicalId":8534,"journal":{"name":"Asian Journal of Pharmaceutical Research and Health Care","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Research and Health Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajprhc.ajprhc_15_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Various malignancies, autoimmune disorders such as rheumatoid arthritis (RA), and elective abortions commonly use methotrexate (MTX) for their treatment, which is a folate antagonist. Although many cases of the common side effects of MTX such as nausea, vomiting, and stomatitis have been reported, very few cases of MTX-induced neutropenia have been found in the literature. We have taken a case of neutropenia that developed after the patient took tablet MTX for RA. The case was studied and the causality assessment of the reported adverse drug reaction showed it to be in the category of “probable” according to the WHO-UMC causality categories.